If you've read anything about BPC-157 in the last 10 years, you have run into the same frustrating pattern: a dense body of promising animal research, a sea of athlete testimonials, and essentially no properly controlled human data. In February 2026, Hudson Biotech began enrolling the first Phase 2 randomised controlled trial of BPC-157 in humans — NCT07437547, a 120-participant, double-blind, placebo-controlled study of acute Grade II hamstring strain. This is the single most important development in BPC-157 research in a decade.
Key Takeaways
- NCT07437547: Randomised, double-blind, placebo-controlled Phase 2 trial — the first properly designed human RCT of BPC-157.
- 120 participants, ages 18–45, with MRI-confirmed Grade II hamstring strain within 72 hours of injury.
- Daily subcutaneous dosing for 14 days on top of a standardised physiotherapy protocol.
- Co-primary endpoints: Time to return to unrestricted sport, and MRI-measured injury volume change at Day 14.
- Trial start: February 2, 2026. Primary completion: February 14, 2027. Full completion: February 17, 2028.
- Does not establish safety or efficacy for other indications (gut, tendon, neurological, systemic healing) — those claims still rest almost entirely on animal data.
Why This Trial Matters So Much
BPC-157's evidence base is lopsided in a way that is unusual even for research peptides. There are:
- Hundreds of rodent studies covering tendon healing, gut mucosal repair, muscle recovery, bone healing, nerve regeneration, cardiovascular effects, and more.
- Essentially no properly controlled human trials. A small 2025 IV pilot in two healthy volunteers showed short-term safety with no adverse events at 10–20 mg doses — but two participants is not a clinical trial.
- Enormous informal user base through research-peptide channels and compounding pharmacies — with wildly varying protocols, no standardised outcomes, and no safety surveillance.
The result is a 30-year gap between the preclinical story and the human data. NCT07437547 is the first study designed to actually close part of that gap.
Trial Design in Detail
Population
- Adults aged 18–45
- Acute posterior thigh pain consistent with hamstring strain, onset within 72 hours before screening
- MRI-confirmed Grade II strain of the biceps femoris, semitendinosus, or semimembranosus — with a measurable lesion volume
The strict acute-injury inclusion window is critical. Previous attempts to collect human BPC-157 data have been muddied by chronic injuries, mixed etiologies, and self-reported outcomes.
Intervention
- Randomisation: 1:1 BPC-157 vs. matching placebo
- Route: Subcutaneous injection, once daily
- Duration: 14 days of active treatment
- Blinding: Double-blind (neither patients nor investigators know assignment)
- Background therapy: All participants follow the same evidence-based physiotherapy protocol, supervised by study physiotherapists
Endpoints
- Co-primary — Time to return to unrestricted sport. A functional, meaningful outcome.
- Co-primary — Change in MRI-measured injury volume at Day 14. An objective imaging-based measure of structural healing.
- Follow-up assessments: Days 3, 7, 14, 28, 56, plus a 3-month post-return-to-play check for recurrence.
The use of both a functional outcome (time to return to sport) and a structural outcome (MRI injury volume) is a well-designed combination — one captures what matters to the athlete, the other captures what the drug is physiologically doing.
What This Trial Will Tell Us
If BPC-157 works in acute Grade II hamstring strain and the trial reads out positive at the primary endpoint:
- Validates one specific use case — acute skeletal muscle injury — with level-1 evidence.
- Opens a plausible regulatory path for a sports-medicine indication, potentially via orphan or specialty pathways.
- Changes nothing about the compounded-peptide market directly, but changes the scientific credibility bar for every future BPC-157 claim.
What This Trial Will Not Tell Us
Equally important to understand what a positive result would not mean:
- It will not validate BPC-157 for tendon healing. Different tissue, different mechanism, different kinetics — needs its own trial.
- It will not validate BPC-157 for gut repair or IBD. The animal data on gut effects uses different dosing routes and different endpoints. A positive hamstring result does not extrapolate.
- It will not establish long-term safety. 14 days of dosing with 3-month follow-up is a short window. Chronic use safety data remains absent.
- It will not validate oral BPC-157. This trial uses subcutaneous injection. Oral formulations have substantially different pharmacokinetics and have never been properly tested in humans.
- It will not clear BPC-157 for FDA-approved use. One Phase 2 trial is a first step, not a final step. FDA approval requires Phase 3 confirmation and typically multiple pivotal studies.
Context: The 2025 IV Pilot
In 2025, Lee and Burgess published a small intravenous pilot study in two healthy adults who received 10 mg of BPC-157 on day 1 and 20 mg on day 2. Key findings:
- No adverse events reported during the study window
- No clinically meaningful changes in vital signs or safety labs
- Plasma concentrations returned to baseline within 24 hours
This was a safety and pharmacokinetic pilot in healthy volunteers — not an efficacy study, not blinded, and not controlled. It cleared a very low bar: BPC-157 at these doses doesn't acutely harm two healthy adults. It did not establish that BPC-157 does anything therapeutically useful.
What to Watch For
Timeline markers for the NCT07437547 trial:
- Early 2027: Primary completion date. First look at co-primary endpoint data likely in Q2 2027.
- Mid-to-late 2027: Peer-reviewed publication of primary results, assuming no unusual delays.
- Early 2028: Full study completion, including extended follow-up data.
If the trial reads out positive, expect a cascade of follow-on human studies in adjacent indications. If it reads out neutral or negative, the compounded-peptide market will likely continue regardless — but the scientific case for therapeutic BPC-157 will become significantly harder to make.
Frequently Asked Questions
Is this the first ever human BPC-157 trial?
It is the first properly designed, randomised, double-blind, placebo-controlled trial. There have been small observational reports, a 2025 IV safety pilot in two volunteers, and various unregistered or industry-sponsored studies, but none of them meet the design standard of NCT07437547.
Why hamstring strain specifically?
Acute Grade II hamstring strain is clinically well-defined, imaging-measurable, has an objective recovery endpoint (return to play), and heals predictably on a timeline short enough for a feasible Phase 2 study. It's also the kind of injury where the animal data on BPC-157 is most directly relevant.
When will the results be available?
Primary completion is February 14, 2027. Full publication typically follows 6–12 months after primary completion, so expect peer-reviewed results in mid-to-late 2027. Preliminary top-line results may be announced earlier via press release or conference presentation.
What dose is being tested?
Hudson Biotech has not publicly disclosed the exact BPC-157 dose used in the trial. The subcutaneous route and once-daily dosing for 14 days are confirmed in the registry listing. Exact mg/kg or fixed-dose figures should be published alongside the primary results.
Does this trial change the legal status of BPC-157?
No. BPC-157 remains an unapproved investigational compound in the United States and most other jurisdictions. The trial being enrolled changes the scientific evidence base, not the regulatory status. Approval would require successful Phase 3 trials and an FDA application.
Can I enroll in this trial?
Eligibility requires an acute Grade II hamstring strain within 72 hours of screening, MRI confirmation of the lesion, and ages 18–45. Current enrollment status and site locations are listed on the ClinicalTrials.gov registry entry (NCT07437547). Contact the sponsor directly for current recruitment status.
What if the trial fails?
A negative or neutral result on the co-primary endpoints would be the most important BPC-157 finding to date — and would significantly undermine the current consumer-market claims about BPC-157 for athletic recovery. It would not rule out activity in other indications (gut, tendon, neurological), but it would reset the bar for future claims.
What else is being studied in humans right now?
Beyond NCT07437547, no other Phase 2 or Phase 3 BPC-157 trials in humans are currently active to meet comparable design standards. The 2025 IV pilot (two healthy volunteers) and various observational reports remain the only other published human-facing data. Multiple registered-but-not-recruiting entries exist, and their trial-registry status should be checked for current recruitment.
Primary sources:
- ClinicalTrials.gov — BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547)
- PeptIQ — BPC-157 Hits a Milestone: The First Controlled Human Trial Is Now Recruiting
- Irvine Health — BPC-157 in 2026: Updated Evidence and First Human Safety Data
- PubMed — Multifunctionality and Possible Medical Application of the BPC-157 Peptide: Literature and Patent Review
- WellFounded — BPC-157 and the Difference Between an Evidence Gap and a Cover-Up
Research disclaimer: BPC-157 is an unapproved investigational research compound. This article summarises registered clinical trial design and published preclinical research for educational purposes. Nothing here constitutes medical advice. Always consult a licensed healthcare provider before considering any peptide therapy.
